Drug-eluting stent in saphenous vein graft lesions

Catheterization and Cardiovascular Interventions

Volumn 71, Issue 7, 2008, Pages 894-895

  Kornowski, Ran ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN; ANTITHROMBOCYTIC AGENT; CARDIOVASCULAR AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METAL;

ATHEROSCLEROTIC PLAQUE; CORONARY ARTERY ATHEROSCLEROSIS; DRUG ELUTING STENT; HUMAN; IN-STENT RESTENOSIS; NOTE; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS; SAPHENOUS VEIN GRAFT; VEIN GRAFT DISEASE; CARDIOVASCULAR DISEASE; GRAFT OCCLUSION; INSTRUMENTATION; MORTALITY; PATIENT SELECTION; PROSTHESIS; RISK ASSESSMENT; SAPHENOUS VEIN; STENT; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TRANSPLANTATION; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; GRAFT OCCLUSION, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; METALS; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PROSTHESIS DESIGN; RISK ASSESSMENT; SAPHENOUS VEIN; SIROLIMUS; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 45849084649     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21615     Document Type: Note

References (13)

1. Douglas JS Jr. Percutaneous intervention in patients with prior coronary bypass surgery. In: Topol EJ, editor. Textbook of Interventional Cardiology, 4th ed. Philadelphia: W.B. Saunders; 2003. pp 317-344.
2. van Beusekom HM, van der Giessen WJ, van Suylen R, Bos E, Bosman FT, Ssrruys PW. Histology after stenting of human saphenous vein bypass graft: Observation from surgically excised grafts 3 to 320 days after stent implantation. J Am Coll Cardiol 1993;21:45-54.
3. Pucelikova T, Mehran R, Kirtane AJ, Kim YH, Fahy M, Weisz G, Lansky AJ, Moussa I, Gray WA, Collins MB, Kodali SK, Stone GW, Moses JW, Leon MB, Dangas G. Short- and long-term outcomes after stent-assisted percutaneous treatment of saphenous vein grafts in the drug-eluting stent era. Am J Cardiol 2008;101:63-68.
4. Ge L, Iakovou I, Sangiorgi GM, Chieffo A, Melzi G, Cosgrave J, Montorfano M. Michev 1, Airoldi F, Carlino M, Corvaja N, Colombo A. Treatment of saphenous vein graft lesions with drug eluting stents. J Am Coll Cardiol 2005;45:989-994.
5. Hoye A. Lemos PA, Arampatzis CA, Saia F, Tanabe K, Degertekin M, Hofma S, McFadden E, Sianos G. Smits PC, van der Giessen WJ, de Feyter P, van Domburg RT, Serruys PW. Effectiveness of the sirolimus-eluting stent in the treatment of saphenous vein graft disease. J Invasive Cardiol 2004;16:230-233.
6. Price MJ, Sawhney N, Kao JA, Madrid A, Schatz RA, Teirstein PS. Clinical outcomes after sirolimus-eluting stent implantation for de novo saphenous vein graft lesions. Catheter Cardiovasc Interv 2005;65:208-211.
7. Lee MS, Shah AP, Aragon J, Jamali A, Dohad S, Kar S, Makkar RR. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv 2005;66:507-511.
8. Chu WW, Rha SW, Kuchulakanti PK, Cheneau E, Torguson R, Pinnow E, Alexieva-Fournadjiev J, Pichard AD, Satler LF, Kent KM, Lindsay J, Waksman R. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol 2006;97:34-37.
9. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Converts C, Bruining N, Van den Branden F, Van Langenhove G. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: Six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol 2006; 48:2423-2431.
10. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Van den Branden F, Van Langenhove G; DELAYED RRISC (Death and Events at Long-term follow-up AnalYsis: Extended Duration of the Reduction of Restenosis In Saphenous vein grafts with Cypher stent) Investigators. Increased late mortality after sirolimus-eluting stents versus bare metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC trial. J Am Coll Cardiol 2007;50:261-267.
11. Bansal D, Sachdeva R, Mehta JL. Percutaneous intervention in saphenous vein bypass graft disease: Case against the use of drug-eluting stents. J Am Coll Cardiol 2008;51:970-971.
12. Ramana RK, Ronan A, Cohoon K, Homan D, Sutherland J, Steen L, Liu J, Loeb H, Lewis BE. Long-term clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft disease. Catheter Cardiovasc Interv (in press).
13. Assali A, Raz Y, Vaknin-Assa, H, Ben-Dor I, Brosh D, Teplitsky I, Fuchs S, Kornowski R. Beneficial 2-years results of drug-eluting stents in saphenous vein graft lesions. Eurointervention (in press).